Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02270502 · ClinicalTrials.gov registry record
Effects of Frailty, Sarcopenia and Muscle Wasting on Outcomes of Patients in the Surgical Intensive Care Unit
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 111
- Enrollment target
NCT02270502: Completed study, sponsored by Massachusetts General Hospital.
NCT02270502 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 111 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02270502 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 111 participants
- Enrollment target
Study Summary
The primary aim of the study is to evaluate consequences of frailty in critically ill patients. We hypothesize that a higher frailty index (based on published questionnaires) predicts a longer surgical intensive care unit and hospital length of stay, less ventilator-free days and a higher likelihood of an adverse discharge disposition. Our secondary aim is to identify muscle-size derived variables that can be used to predict frailty. We hypothesize that a low skeletal muscle mass measured by ultrasound can be used to quantify frailty, and to also predict the outcome of SICU patients, expressed as longer stay in the surgical intensive care unit and longer stay in the hospital, less ventilator-free days and a higher likelihood of an adverse discharge disposition. Our third aim is to examine potential triggers of muscle wasting in critically ill patients. Muscle wasting will be assessed by repetitive ultrasound measurements of muscle mass. We hypothesize that a significant decrease in skeletal muscle mass predicts longer stay at the surgical intensive care unit and longer hospital length of stay, less ventilator-free days and adverse discharge disposition.
Primary Outcome
Time from study inclusion to SICU discharge, an expected time of 2 days to 2 weeks.
Interventions
- DEVICE Ultrasound Philips CX50
- OTHER Frailty Index Questionnaire
- OTHER Muscle strength tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 111 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-12 |
What the finished NCT02270502 record still lists
NCT02270502 is an observational study that tracks outcomes without assigning an intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Ultrasound Philips CX50 is the first listed.
NCT02270502 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02270502 about?
NCT02270502 is a clinical study titled "Effects of Frailty, Sarcopenia and Muscle Wasting on Outcomes of Patients in the Surgical Intensive Care Unit". The primary aim of the study is to evaluate consequences of frailty in critically ill patients. We hypothesize that a higher frailty index (based on published questionnaires) predicts a longer surgical intensive care unit and hospital length of stay, less ventilator-free days and a higher likelihood...
What is the current status of trial NCT02270502?
This trial is currently completed. The enrollment target is 111 participants. The study started on 2014-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02270502?
The interventions under investigation include: Ultrasound Philips CX50 (DEVICE), Frailty Index Questionnaire (OTHER), Muscle strength tests (OTHER).
Who is sponsoring clinical trial NCT02270502?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03875716 · 111 participants · NA
Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma
- NCT04693468 · 111 participants · Phase 1
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- NCT05263050 · 111 participants · Phase 2
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
- NCT05600842 · 111 participants
De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia